Shares of Lexeo Therapeutics (LXEO) jumped on Monday after the company announced a regulatory milestone for its lead gene therapy candidate, LX2006. The stock was up 12.81% to $4.935 at the time of publication, according to market data.
The company has finalized the protocol for its SUNRISE-FA 2 pivotal trial, which will evaluate LX2006 in patients with Friedreich ataxia cardiomyopathy — a rare, fatal heart condition. Enrollment is set to kick off by the end of June 2026, with the first patient expected to be dosed shortly after.
Lexeo is targeting a topline data readout in the second half of 2027, followed by an FDA submission under the accelerated approval pathway in the first half of 2028. That timeline suggests the company is betting on a relatively fast path to market if the data holds up.
From a technical perspective, Lexeo shares are currently trading at $4.51, about 1.7% above their 20-day simple moving average of $4.72 — a sign of short-term bullish momentum. But the picture gets murkier when you zoom out. The stock sits 13.3% below its 50-day SMA of $5.53, and the MACD indicator is below its signal line, hinting that the recent rally may be losing steam.
Key levels to watch: resistance at $5.00, where rebounds have stalled before, and support at $4.00, a level where buyers have historically stepped in. If Lexeo can break through $5.00, it could signal a stronger uptrend; if it slips below $4.00, the bears might take control.
For now, the market is cheering the regulatory clarity. But as with any biotech stock, the real test will come when the data rolls in.
